If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket

The article says that when Wall Street's growth-at-any-price trade cools, capital typically rotates into profitable, cash-generative healthcare stocks. It frames this as a recurring pattern across monetary cycles rather than a specific company or event. The takeaway is a defensive sector rotation signal with limited immediate market impact.